Monday, October 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Deutsche Bank Analyst Downgrades Grifols to Sell Rating Amid Growing Skepticism

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Unlocking Value: The Economic Potential of Iron-Titanium-Vanadium Projects
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On March 12, 2024, analyst Emmanuel Papadakis from Deutsche Bank made a bold move by downgrading Grifols (NASDAQ: GRFS) from a “Hold” to a “Sell” rating. This decision reflects a growing sentiment among analysts who are becoming increasingly skeptical of Grifols due to lackluster guidance and perceived issues with transparency and communication. As a result, the stock has taken a hit, with several firms following suit and adjusting their recommendations for the company.

GRFS Stock Price Drops 7.09% in Regular Trading Hours, Sees After-Hours Rebound

On March 12, 2024, GRFS stock experienced a significant drop in its price, closing at $6.29, which was a decrease of $0.48 or 7.09% from the previous market close. Despite the drop in price during regular trading hours, GRFS stock saw a slight increase of $0.11 in after-hours trading. This after-hours activity suggests that there may be some renewed interest or optimism in the stock, potentially leading to a rebound in the coming days. Investors and analysts will be closely monitoring the performance of GRFS stock in the coming days to see if the after-hours gain will be sustained and if the stock can recover from its recent decline.

GRFS Stock Performance Analysis: Revenue, Net Income, and EPS Decline in Q1 2024

On March 12, 2024, GRFS stock experienced a mixed performance based on the financial data provided. The total revenue for the company was $5.83 billion over the past year, but this represented a decrease of 4.22% compared to the previous year. In the first quarter of 2024, the total revenue further decreased to $1.43 billion, marking an 8.58% decline since the last quarter.

The net income for GRFS was $216.07 million over the past year, but this figure decreased by a significant 69.36% compared to the previous year. However, the net income held flat at $156.50 million in the first quarter of 2024, showing no change since the last quarter.

Earnings per share (EPS) for GRFS stood at $0.32 over the past year, which was a 69.23% decrease from the previous year. The EPS remained flat at $0.23 in the first quarter of 2024, showing no change compared to the last quarter.

Overall, the financial performance of GRFS stock on March 12, 2024, reflected a decline in total revenue, net income, and earnings per share compared to the previous year. However, the company managed to maintain its net income and EPS at the same level since the last quarter. Investors and analysts may closely monitor these financial indicators to assess the company’s future growth prospects and stock performance.

Tags: GRFS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Food Producers Stock Market Today

Product Recall Great Value Honey Roasted Cashews with Undeclared Coconut and Milk

Investment

Unveiling the Power of Convertible Notes: A New Avenue for Funding Innovation and Growth

Fur ban

The Rise of Ethical Consumerism: How Bans on Mink Fur Farming Impact Fashion Industry Economics

Recommended

AtriCure Stock

Institutional Investors and Insiders Diverge on AtriCure’s Prospects

1 month ago
Eli Lilly Stock

Pharmaceutical Sector Surges as Eli Lilly Leads Market Rally

4 days ago

Anticipated Success for AGCO Corporation in 2024

2 years ago
Thyssenkrupp Stock

Thyssenkrupp’s Strategic Crossroads: Indian Bid Reshapes Steel Unit’s Future

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power Realty Income Red Cat Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Mondelez Shares Face Critical Test Amid Commodity Pressures

Autodesk’s AI Transformation Captivates Investors

Regeneron Receives Key FDA Approval for Pediatric Treatment

aTyr Pharma Shares Plummet Following Clinical Trial Failure

Microvast Shares Surge Following Capital Raise Announcement and Bullish Analyst Outlook

Thermo Fisher’s Strategic Moves: Billion-Dollar Vaccine Deal and AI Partnership Fuel Growth

Trending

Opendoor Technologies Stock
E-Commerce

Leadership Shakeup Ignites Opendoor Stock Surge

by Felix Baarz
October 6, 2025
0

Opendoor Technologies shares surged an extraordinary 36% in pre-market trading following the company's September 10 announcement of...

L3Harris Technologies Stock

L3Harris Shares Soar Amid Defense Sector Surge, But Caution Prevails

October 6, 2025
Canaan Stock

Mining Giant’s Major Order Fails to Prevent Stock Plunge

October 6, 2025
Mondelez Stock

Mondelez Shares Face Critical Test Amid Commodity Pressures

October 6, 2025
Autodesk Stock

Autodesk’s AI Transformation Captivates Investors

October 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Leadership Shakeup Ignites Opendoor Stock Surge
  • L3Harris Shares Soar Amid Defense Sector Surge, But Caution Prevails
  • Mining Giant’s Major Order Fails to Prevent Stock Plunge

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com